Jazz Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JAZZ PHARMS, and what generic alternatives to JAZZ PHARMS drugs are available?
JAZZ PHARMS has four approved drugs.
There are thirty-nine US patents protecting JAZZ PHARMS drugs.
There are one hundred and eighty-six patent family members on JAZZ PHARMS drugs in twenty-eight countries and sixty-seven supplementary protection certificates in eight countries.
Summary for Jazz Pharms
| International Patents: | 186 |
| US Patents: | 39 |
| Tradenames: | 4 |
| Ingredients: | 4 |
| NDAs: | 4 |
Drugs and US Patents for Jazz Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz Pharms Inc | DEFITELIO | defibrotide sodium | SOLUTION;INTRAVENOUS | 208114-001 | Mar 30, 2016 | RX | Yes | Yes | 11,236,328 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 10,709,671 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,160,795 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,400,055 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | RX | Yes | Yes | 11,633,369 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Jazz Pharms | XYREM | sodium oxybate | SOLUTION;ORAL | 021196-001 | Jul 17, 2002 | RX | Yes | Yes | 11,253,494*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Jazz Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Jazz Pharms Res | EPIDIOLEX | cannabidiol | SOLUTION;ORAL | 210365-001 | Sep 28, 2018 | 10,195,159 | ⤷ Try a Trial |
| Jazz Pharms | LUVOX CR | fluvoxamine maleate | CAPSULE, EXTENDED RELEASE;ORAL | 022033-001 | Feb 28, 2008 | 7,465,462 | ⤷ Try a Trial |
| Jazz Pharms | LUVOX CR | fluvoxamine maleate | CAPSULE, EXTENDED RELEASE;ORAL | 022033-002 | Feb 28, 2008 | 7,465,462 | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JAZZ PHARMS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 100 mg | ➤ Subscribe | 2009-04-20 |
| ➤ Subscribe | Extended-release | 150 mg | ➤ Subscribe | 2009-04-13 |
| ➤ Subscribe | Oral Solution | 500 mg/mL | ➤ Subscribe | 2010-07-08 |
International Patents for Jazz Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2020006954 | ⤷ Try a Trial |
| Mexico | 2021003331 | ⤷ Try a Trial |
| European Patent Office | 3735964 | ⤷ Try a Trial |
| Portugal | 3206716 | ⤷ Try a Trial |
| Lithuania | 3206715 | ⤷ Try a Trial |
| Canada | 3232241 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Jazz Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0806968 | SPC/GB07/011 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: GADOFOSVESET TRISODIUM; REGISTERED: UK EU/1/05/313/001 20051003; UK EU/1/05/313/002 20051003; UK EU/1/05/313/003 20051003; UK EU/1/05/313/004 20051003; UK EU/1/05/313/005 20051003; UK EU/1/05/313/006 20051003; UK EU/1/05/313/007 20051003; UK EU/1/05/313/008 20051003; UK EU/1/05/313/009 20051003 |
| 1499331 | SPC/GB13/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313 |
| 2932970 | 18C1043 | France | ⤷ Try a Trial | PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518 |
| 2822954 | SPC/GB18/031 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM.; REGISTERED: UK EU/1/18/1289/001(NI) 20180625; UK EU/1/18/1289/002(NI) 20180625; UK PLGB 11972/0008 20180625 |
| 2932970 | SPC/GB18/041 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION COMPRISING DOLUTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. DOLUTEGRAVIR SODIUM) AND RILPIVIRINE OR A PHARAMACEUTICALLY ACCEPTABLE SALT THEREOF (E.G. RILPIVIRINE HYDROCHLORIDE); REGISTERED: UK EU/1/18/1282 20180518; UK PLGB 35728/0055 20180518; UK PLGB 35728/0056 20180518; UK PLGB 35728/0057 20180518 |
| 2203431 | 1590018-6 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
